The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10237 malaria professionals are enjoying the free benefits of MalariaWorld today

antibody

G6PD A−variant influences the antibody responses to Plasmodium falciparum MSP2

July 21, 2011 - 14:21 -- Patrick Sampao
Author(s): 
David Courtin, Jacqueline Milet, Florence Migot-Nabias, et al.
Reference: 
Infection, Genetics and Evolution, Volume 11, Issue 6, August 2011, Pages 1287-1292

This latter finding is suggestive of qualitative and/or quantitative reduction of exposure to malarial antigens related to this genetic variant, leading to weaker stimulation of specific antibody responses.

A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice

August 16, 2010 - 14:24 -- Patrick Sampao
Author(s): 
Fernanda G., Daniel Y., et al
Reference: 
Vaccine, Volume 28, Issue 38, 31 August 2010, Pages 6183-6190

These results demonstrate that a recombinant protein containing PvAMA-1 DII is immunogenic when administered in different adjuvant formulations, and indicate that this region of the AMA-1 protein should continue to be evaluated as part of a subunit vaccine against vivax malaria.

Product: 
Medical Treatment: 

The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among species

June 2, 2010 - 12:03 -- Patrick Sampao
Author(s): 
Lediya C., Yimin W., et al.
Reference: 
Vaccine, Volume 28, Issue 27, 17 June 2010, Pages 4423-4429

In this study, we purified Pfs25-specific IgGs to convert antibody titer to μg/mL and determined the amount of antibody required to inhibit 50% of oocyst development (IC50).

Medical Condition: 
Medical Treatment: 

Immunology: Boosting antibody responses to Plasmodium falciparum merozoite antigens in children with highly seasonal exposure to infection

March 11, 2010 - 13:14 -- Patrick Sampao
Author(s): 
O. J. Akpogheneta, S. Dunyo, M. Pinder, D. J. Conway
Reference: 
Parasite Immunology,Volume 32, Issue 4, April 2010, Pages: 296-304

Longitudinal cohort studies are important to describe the dynamics of naturally acquired antibody response profiles to defined Plasmodium falciparum malaria antigens relative to clinical malaria episodes.

Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Long-Lived Antibody and B Cell Memory Responses to the Human Malaria Parasites, Plasmodium falciparum and Plasmodium vivax

February 27, 2010 - 09:29 -- Ingeborg van Schayk
Author(s): 
Jiraprapa Wipasa, Chaisuree Suphavilai, Lucy C. Okell, Jackie Cook, Patrick H. Corran, Kanitta Thaikla, Witaya Liewsaree, Eleanor M. Riley, Julius Clemence R. Hafalla
Reference: 
PLoS Pathog 6(2): e1000770

In this study, we analysed the longevity of both antibody and B cell memory responses to malaria antigens among individuals who were living in an area of extremely low malaria transmission in northern Thailand, and who were known either to be malaria naïve or to have had a documented clinical attack of P. falciparum and/or P. vivax in the past 6 years.

Country: 

What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity

October 29, 2009 - 12:37 -- Ingeborg van Schayk
Author(s): 
Samson M Kinyanjui, Philip Bejon, Faith H Osier, Peter C Bull, Kevin Marsh
Reference: 
Malaria Journal 2009, 8:242 (28 October 2009)

Failure to distinguish between individuals who do not get a clinical episode during follow-up because they were unexposed and those who are genuinely immune undermines our ability to assign a protective role to immune responses against malaria. The brevity of antibodies responses makes it difficult to assign the true serological status of an individual at any given time, i.e. those positive at a survey may be negative by the time they encounter the next infection.

Medical Condition: 
Subscribe to RSS - antibody